Economic evaluation in stroke research: An introduction

Cerebrovascular Diseases

Volumn 11, Issue 2, 2001, Pages 82-91

  Evers, Silvia M A A ^a,c   Goossens, Mariëlle E J B ^b   Ament, André J H A ^a   Maarse, Johannes A M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE FOR REHABILITATION RESEARCH   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Economics; Quality of life; Stroke assessment

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE FACILITY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; RESOURCE MANAGEMENT; STROKE;

CEREBROVASCULAR ACCIDENT; COSTS AND COST ANALYSIS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RESEARCH;

EID: 0035101902     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047617     Document Type: Article

References (67)

1. Cost of medical care after first-ever stroke in the Netherlands
2. The economic impact of stroke
3. The financial burden of stroke and the economic evaluation of treatment alternatives
4. Cost of stroke in the Netherlands
5. Cost of stroke
6. The cost of stroke to the national service in Scotland
7. Ischaemic stroke in New Zealand: An economic study
8. Lifetime cost of stroke in the United States
9. The cost of cerebrovascular accidents in France in 1982
10. Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada
11. A comparative review of pharmacoeconomic guidelines
12. Health economics: Has it fulfilled its potential?
13. The role of perspective in defining economic measures for the evaluation of medical technology
14. Cost-benefit and cost-effectiveness analysis in health care: Growth and composition of the literature
15. Principles of cost-effective resource allocation in health care organization
16. Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly?
17. Economic assessment of back pain interventions
18. Economic evaluation of mental health care interventions: A review
19. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
20. Something rotten in the state of clinical and economic evaluations?
21. Making cost assessments based on RCTs more useful to decision-makers
22. The stroke prevention patient outcomes research team: Goals and methods
23. The stroke P.O.R.T.: Secondary and tertiary prevention of ischemic stroke. Stroke prevention patient outcomes research team
24. The stroke prevention policy model: Linking evidence and clinical decisions
25. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke
26. Health-related quality of life outcomes in stroke
27. A comparison of five stroke scales with measures of disability, handicap, and quality of life
28. Quality of life after stroke: Impact of stroke type and lesion location
29. Measuring quality of life in stroke
30. Is the EuroQol a valid measure of health-related quality of life after stroke?
31. Is the SF-36 suitable for assessing health status of older stroke patients?
32. Quality of life in patients and partners after aneurysmal subarachnoid hemorrhage
33. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke: United Kingdom collaborators in the International Stroke Trial
34. A stroke-adapted 30-item version of the Sickness Impact Profile to assess quality of life (SA-SIP30)
35. Are proxy assessments of health status after stroke with the EuroQol questionnaire feasible, accurate, and unbiased?
36. A randomised comparison of the EuroQol and Short Form-36 after stroke: United Kingdom collaborators in the International Stroke Trial
37. Assessing quality of life after stroke: The value and limitations of proxy ratings
38. Use of the SF-36 questionnaire in cerebrovascular disease
39. Validation of the Short Form 36 (SF-36) healthy survey questionnaire among stroke patients
40. Outcome measurement in economic evaluation
41. Pitfalls in neuroepidemiologic research
42. Response-shift bias: A challenge to the assessment of patients' quality of life in cancer clinical trials
43. Estimating costs in the economic evaluation of medical technologies
44. Cost-effective intervention in stroke
45. The cost diary: A method to measure the direct and indirect costs in a cost effectiveness research
46. The distinction between cost and charges
47. Towards a new approach for estimating indirect costs of disease
48. The friction cost method for measuring indirect cost of disease
49. Cost-of-illness studies a major headache?
50. Cost-of-illness methodology: A guide to current practices and procedures
51. Cost-of-illness studies of stroke
52. Cost-effectiveness league tables: More harm than good?
53. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
54. Emerging standardization in pharmacoeconomics
55. A clinician's guide to cost-effectiveness
56. Cost of acute stroke care in Toronto, Canada
57. Costs of stroke in Sweden: A national perspective
58. Utilization of health care resources after stroke: A population-based study of 258 hospitalized cases followed during the first year